TABLE 9.
Outlook of COVID-19 vaccine development.
| Vaccine Candidate | Country | Manufacture (Sponsor) | Phase |
|---|---|---|---|
| Sputnik-V/Gam-COVID-Vac | Russia | Gamaleya research Institute | 3 |
| Inactivated vaccine (COVID-19 vaccine) | China | Wuhan Institute of biological products/Sinopharm | 3 |
| ChAdOX1-S | U.S. | University of Oxford/AstraZeneca | 3 |
| Adenobased (rAd26 + rAd5-s) | Russia | Gamaleya research Institute | 3 |
| Ad26CoVS1 | Belgium | Janssen pharmaceutical companies | 3 |
| Full length recombinant SARS-CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M | UK | Novavax | 3 |
| LNP-encapsulated mRNA | USA | Moderna/N1 AID | 3 |
| Adjuvanted recombinant protein (RBD-dimer) | China | Anhui Zhifei longcom biopharmaceutical Chinese Academy | 2 |
| mRNA vaccine | Germany | Curevac | 2 |
| DNA-vaccine (GX-19) | South Korea | Genexine-consortium | ½ |